Verona Pharma plc, a biopharmaceutical company, is among the 12 best performing healthcare stocks to buy right now. Their lead product, Ohtuvayre, received FDA approval in June 2024 for COPD treatment and has seen rapid adoption. Shareholders recently approved a $10 billion acquisition by Merck & Co., Inc., expected to close on October 7, 2025. Verona Pharma continues to show strong financial growth, with Q1 2025 net revenues reaching $76.3 million. While VRNA is considered a good investment, some believe other AI stocks offer greater potential. Ohtuvayre boosts Merck’s respiratory portfolio and is being evaluated for additional conditions.

Read more at Yahoo Finance: Verona Pharma plc (VRNA) Nears $10B Merck Buyout, Ohtuvayre Boosts COPD Portfolio